Sherbrooke Park Advisers LLC Cytek Biosciences, Inc. Transaction History
Sherbrooke Park Advisers LLC
- $436 Billion
- Q3 2024
A detailed history of Sherbrooke Park Advisers LLC transactions in Cytek Biosciences, Inc. stock. As of the latest transaction made, Sherbrooke Park Advisers LLC holds 104,386 shares of CTKB stock, worth $674,333. This represents 0.13% of its overall portfolio holdings.
Number of Shares
104,386
Previous 29,984
248.14%
Holding current value
$674,333
Previous $167 Million
245.64%
% of portfolio
0.13%
Previous 0.03%
Shares
4 transactions
Others Institutions Holding CTKB
# of Institutions
134Shares Held
71.7MCall Options Held
400Put Options Held
0-
Black Rock Inc. New York, NY17.1MShares$110 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$76.1 Million0.0% of portfolio
-
Brown Capital Management LLC Baltimore, MD9.49MShares$61.3 Million1.15% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E96.66MShares$43 Million0.85% of portfolio
-
State Street Corp Boston, MA4.17MShares$26.9 Million0.0% of portfolio
About Cytek Biosciences, Inc.
- Ticker CTKB
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 134,627,008
- Market Cap $870M
- Description
- Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers ...